

SUMMARY OF INTERVIEW

Attendees, Date and Type of Interview

The telephonic interview was conducted on April 6, 2010 and attended by Examiner Sznaidman and Che Chereskin.

Exhibits and/or Demonstrations

none

Identification of Claims Discussed

all pending

Identification of Prior Art Discussed

Ishida, et al.

Proposed Amendments

none

Principal Arguments and Other Matters

The Examiner agreed that the claimed compound is different from the compound of Ishida, et al. and that it has a different mechanism of action. However, he maintained that it is necessary to show an effect on a different patient population or a different result on the same patient population to overcome the rejection.

The Examiner stated that the data in the specification was insufficient because the comparative examples were not done with compounds corresponding to the disclosure of Ishida, et al. The Examiner stated that the Tada Declaration submitted with the response of April 22, 2009 was insufficient to overcome the rejection because the data demonstrates a different mechanism of action, but not a different effect on a different patient population. The Examiner further clarified that it would be convincing if centaurein demonstrated a different or additional or synergistic (with Nobletin, for example) effect on the same patient population.

Results of Interview

Applicants will consider submission of additional supporting data.